SCHEMBL6079519

SCHEMBL6079519

COC(=O)c1cc(O)c2c(Cl)cc(Cl)c(OCc3ccccc3)c2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.54
HPGD P15428 1/20 0.54
NOTUM Q6P988 1/20 0.45
ALDH1A1 P00352 3/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NQO2 P16083 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 4/20 0.41
TDP1 Q9NUW8 2/20 0.41
CNR1 P21554 1/20 0.41
ADCYAP1R1 P41586 1/20 0.40
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6592534 0.90 MCL1 (0.44) LMNAHPGDKDM4ETP53THRB
SCHEMBL6080902 0.82 NQO2 (0.50) HPGDNOTUMALDH1A1NQO2KDM4E
SCHEMBL6080117 0.77 LMNA (0.53) LMNAHPGDNOTUMALDH1A1USP2
SCHEMBL6080412 0.77 LMNA (0.47) LMNAHPGDNOTUMUSP2CYP1A2
SCHEMBL6078790 0.77 NQO2 (0.52) LMNANOTUMALDH1A1NQO2KDM4E
SCHEMBL6079781 0.76 LMNA (0.46) LMNAHPGDNOTUMALDH1A1USP2
SCHEMBL6080335 0.76 LMNA (0.46) LMNAHPGDNOTUMALDH1A1KDM4E
SCHEMBL1458077 0.76 LMNA (0.82) LMNAHPGDNOTUMALDH1A1USP2
SCHEMBL6593961 0.76 TPMT (0.48) LMNAHPGDALDH1A1HSD17B10NQO2
SCHEMBL6080259 0.75 MRGPRX4 (0.47) LMNAHPGDNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL LMNA 2027/4885HPGD 336/4885NOTUM 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.